# Study to Evaluate the Efficacy and Safety of GX-E2 in the Anemic Patients Diagnosed With Chronic Kidney Disease (CKD)

> **NCT02044653** · PHASE2 · COMPLETED · sponsor: **Genexine, Inc.** · enrollment: 257 (actual)

## Conditions studied

- Anemia
- Chronic Kidney Disease

## Interventions

- **DRUG:** GX-E2
- **DRUG:** GX-E2
- **DRUG:** GX-E2
- **DRUG:** NESP
- **DRUG:** MIRCERA

## Key facts

- **NCT ID:** NCT02044653
- **Lead sponsor:** Genexine, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-15
- **Primary completion:** 2017-04-20
- **Final completion:** 2017-04-20
- **Target enrollment:** 257 (ACTUAL)
- **Last updated:** 2017-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02044653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02044653, "Study to Evaluate the Efficacy and Safety of GX-E2 in the Anemic Patients Diagnosed With Chronic Kidney Disease (CKD)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02044653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*